{"id":"NCT04102579","sponsor":"Neurocrine Biosciences","briefTitle":"Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-13","primaryCompletion":"2021-10-15","completion":"2021-10-26","firstPosted":"2019-09-25","resultsPosted":"2023-10-11","lastUpdate":"2023-10-11"},"enrollment":128,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chorea, Huntington"],"interventions":[{"type":"DRUG","name":"Valbenazine","otherNames":["NBI-98854"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Valbenazine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.","primaryOutcome":{"measure":"Change From Screening Period Baseline to Maintenance Period in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) Score.","timeFrame":"Baseline (average of screening and Day -1), maintenance (average of Weeks 10 and 12)","effectByArm":[{"arm":"Valbenazine","deltaMin":-4.6,"sd":0.43},{"arm":"Placebo","deltaMin":-1.44,"sd":0.44}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":46,"countries":["United States","Canada"]},"refs":{"pmids":["37210099","32250312"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":64},"commonTop":["Fall","Fatigue","Somnolence","Akathisia","Rash"]}}